Public Release:  New discovery by Harvard scientists aims to correct cellular defects leading to diabetes

New research in the FASEB Journal reports that the G6PD protein, which produces the essential antioxidant NAPDH, could prevent the death of pancreatic beta cells, the root cause of diabetes

Federation of American Societies for Experimental Biology

A new research discovery published online in the FASEB Journal (http://www.fasebj.org) may change the perception and treatment of diabetes. That's because scientists have moved closer toward correcting the root cause of the disease rather than managing its symptoms. Specifically researchers identified a protein (G6PD protein) and its antioxidant product (NAPDH) that both prevent the death and promote the growth of cells which produce and release insulin in the pancreas (beta cells).

"Abnormally high levels of oxidants are thought to be a major cause of diabetes and the complications of diabetes, as well as many other diseases," said Robert C. Stanton, M.D., co-author of the study, from Joslin Diabetes Center in Boston. "By understanding the specific defects in processes that either produce too many oxidants or not enough antioxidants, a new era of highly specific, targeted treatments will emerge that very effectively treat or possibly prevent many of these diseases."

To make this discovery, Stanton and colleagues studied beta cells from humans and mice to determine the effects of increasing sugar on the cells, the G6PD protein, and NADPH antioxidant. Using biochemical and molecular biology techniques, researchers measured levels of various chemicals, proteins and markers of both cell growth and death. Results showed that increasing the level of sugar causes a decrease in NADPH and increased beta cell death. Additionally, tweaking the level of NADPH higher prevented the negative effects of increased sugar. Increasing the activity of G6PD rescued the beta cells from cell death, leading researchers to conclude that treatments that directly prevent G6PD decrease or promote G6PD increases could hold great promise in treating diabetes.

"Even before the 'omic revolution, the cause and cure of diabetes have long been sought," said Gerald Weissmann, M.D., Editor-in-Chief of the FASEB Journal. "This research discovery, which identifies a key enzyme that regulates oxidation and pancreatic cell death, brings us closer than ever to getting at the root of diabetes."

###

Receive monthly highlights from The FASEB Journal by e-mail. Sign up at http://www.faseb.org/fasebjournalreaders.htm. The FASEB Journal (http://www.fasebj.org) is published by the Federation of the American Societies for Experimental Biology (FASEB). The journal has been recognized by the Special Libraries Association as one of the top 100 most influential biomedical journals of the past century and is the most cited biology journal worldwide according to the Institute for Scientific Information. FASEB is composed of 23 societies with more than 90,000 members, making it the largest coalition of biomedical research associations in the United States. FASEB enhances the ability of biomedical and life scientists to improve-through their research-the health, well-being and productivity of all people. Its mission is to advance health and welfare by promoting progress and education in biological and biomedical sciences through service to our member societies and collaborative advocacy.

Details: Zhaoyun Zhang, Chong Wee Liew, Diane E. Handy, Yingyi Zhang, Jane A. Leopold, Ji Hu, Lili Guo, Rohit N. Kulkarni, Joseph Loscalzo, and Robert C. Stanton. High glucose inhibits glucose-6-phosphate dehydrogenase, leading to increased oxidative stress and -cell apoptosis
FASEB J. doi:10.1096/fj.09-136572 ; http://www.fasebj.org/cgi/content/abstract/fj.09-136572v1

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.